Pricing Log in Create free account

Eupraxia Pharmaceuticals Inc. (EPRX) vs Gyre Therapeutics, Inc. (GYRE)

Eupraxia Pharmaceuticals Inc. and Gyre Therapeutics, Inc. are both Biotechnology companies. Eupraxia Pharmaceuticals Inc. and Gyre Therapeutics, Inc. are of similar size ($429.1M and $425.2M). Eupraxia Pharmaceuticals Inc. has the higher net margin (0.00% vs −21.5%) and the higher return on invested capital (0.00% vs −8.51%). Across the 12 metrics below, Gyre Therapeutics, Inc. leads on 7 and Eupraxia Pharmaceuticals Inc. on 5.

Valuation

Metric EPRX GYRE Biotechnology median
P/E n/m n/m 10.60
P/S n/m 4.12 9.40
P/B 4.52 3.47 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales n/m 3.55 9.02
Earnings yield (14.46%) (5.93%) (32.88%)
Free cash flow yield (8.45%) (5.07%) (23.13%)

Profitability

Metric EPRX GYRE Biotechnology median
Gross margin — 91.71% 68.51%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% (21.46%) 0.00%
Free cash flow margin 0.00% (19.94%) 0.00%
Return on equity (117.82%) (18.54%) (51.96%)
Return on assets (64.44%) (14.49%) (46.06%)
Return on invested capital 0.00% (8.51%) 0.00%

Growth

Metric EPRX GYRE Biotechnology median
Revenue growth (TTM) — 13.51% 6.76%
EPS growth (last fiscal year) (35.53%) (60.00%) 29.88%
Revenue growth, 5-year CAGR — 40.96% 9.75%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric EPRX GYRE Biotechnology median
Debt to equity 0.01 0.00 0.00
Current ratio 16.00 4.32 4.97
Net debt to EBITDA 2.11 (3.74) 1.01

Dividend

Metric EPRX GYRE Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric EPRX GYRE Biotechnology median
Market cap 429.13m 425.20m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack